Exclusion Criteria:~* Evidence of clinically relevant neurological disorder(s) other than probable AD~* History
of blood coagulation disorders or hypercoagulability; any concurrent use of an anticoagulant therapy. (e.g.,
heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors). Use of antiplatelet drugs (e.g., aspirin or
clopidogrel) is acceptable.~* Unstable coronary heart disease, e.g. myocardial infarction or severe or unstable
angina in the 6 months prior to dosing.~* Moderate to severe congestive heart failure (New York Association
Class III or IV).~* Poorly controlled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or
diastolic blood pressure of 100 mmHg or higher) despite treatment during the 3 months prior to dosing, or
treatment refractory high blood pressure, defined as treatment requiring 3 or more antihypertensives from
different classes.~* Prior hypersensitivity reaction to any human blood product or intravenous infusion; any
known clinically significant drug allergy.~* Treatment with any human blood product, including transfusions and
intravenous immunoglobulin, during the 6 months prior to screening.~* History of immunoglobulin A (IgA),
haptoglobulin or C1 inhibitor deficiency; stroke, anaphylaxis, or thromboembolic complications of intravenous
immunoglobulins.~* Hemoglobin <10 g/dL in women; and <11 g/dL in men.
